Phase 3 Recruiting Network
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BR…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06475989
Locations: - Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
+ 109 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears …
Sponsor: Vanderbilt University Medical Center
NCT ID: NCT05999630
Locations: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Locations: - Local Institution - 2129 — Duarte, California
- Local Institution - 2120 — Glendale, California
- Local Institution - 2136 — La Jolla, California
+ 46 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Locations: - Clinical Trial Site — Phoenix, Arizona
- Clinical Trial Site — Phoenix, Arizona
- Clinical Trial Site — New Haven, Connecticut
+ 11 more sites in the U.S.
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Locations: - Banner Health- MD Anderson Cancer Center — Gilbert, Arizona
- University of Colorado - Aurora Cancer Center — Aurora, Colorado
- Georgetown University Lombardi Cancer Center — Washington D.C., District of Columbia
+ 7 more sites in the U.S.
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The resear…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06007924
Locations: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
+ 4 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Locations: - Sarah Cannon Research Institute — Denver, Colorado
- Sylvester Comprehensive Cancer Center - University of Miami Health System — Miami, Florida
- Massachusetts General Hospital — Boston, Massachusetts
+ 3 more sites in the U.S.
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Locations: - Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
- Moffitt — Tampa, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
+ 3 more sites in the U.S.
Phase 2 Recruiting Academic/Other
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research s…
Sponsor: Massachusetts General Hospital
NCT ID: NCT05668962
Locations: - MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Moffitt Cancer Center — Tampa, Florida
- Massachusetts General Hospital — Boston, Massachusetts
+ 3 more sites in the U.S.
Phase 2 Recruiting Academic/Other
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05783323
Locations: - University of California, San Francisco — San Francisco, California
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- St. Jude Children's Research Hospital — Memphis, Tennessee
+ 2 more sites in the U.S.
Phase 2 Recruiting Academic/Other
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06458036
Locations: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- St. Jude Children's Research Hospital — Memphis, Tennessee
- MD Anderson Cancer Center — Houston, Texas
+ 1 more site in the U.S.
Phase 2 Recruiting Academic/Other
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100…
Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT03099356
Locations: - University of Michigan Cancer Center — Ann Arbor, Michigan